Trevena Inc TRVN

Healthcare Biotechnology

Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. The Company has one approved product in the United States, OLINVYK (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s pipeline includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder. TRV045 is a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. TRV734 is a small molecule G-protein biased ligand of the mu opioid receptor (MOR).

OTCPK:TRVN - Post by User

Trevena Inc

Bullboard Posts

Comment by ERTguyon Oct 06, 2018 12:41pm

104 Views

Post# 28757513

RE:TRVN on a RUN...

Gekko you old dog you still on this company? I actually have been trading the run up and reacquired a small position into the weekend. I’m interested to see what happens leading up to october 11th when I believe their drug is getting presented to the FDA? I’m probably going to increase on monday and hopefully able to lock in some profit holding a smaller position into the end of the week. This thing could really take off

Bullboard Posts

Harris or Trump? What scenarios can the TSX expect?